Physician profile
Chase S Hall
NPI 1659666709
$329,358.29
in general payments reported to CMS, 2019-2025
11 companies · $139K in 2025
The $139K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $14K · 2021: $28K · 2022: $23K · 2023: $6,503 · 2024: $120K · 2025: $139K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $217K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Travel and Lodging: $9,510 · Food and Beverage: $2,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $217,165.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,305.00 |
| Travel and Lodging | $9,510.40 |
| Food and Beverage | $2,941.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Polarean, INC. | $166,032.75 | 2024-2025 | Xenoview |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105,071.22 | 2019-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $57,254.26 | 2023-2025 | Shingrix |
| United Therapeutics Corporation | $406.43 | 2024-2025 | Tyvaso, Tyvaso |
| Ani Pharmaceuticals, INC. | $209.04 | 2023 | Purified Cortrophin Gel |
| Siemens Medical Solutions USA, INC. | $166.93 | 2023 | Naeotom Alpha, Magnetom Altea |
| Genentech USA, INC. | $117.85 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $39.27 | 2019 | |
| Carestream Dental, LLC | $33.78 | 2019 | |
| Shire North American Group INC | $14.39 | 2019 | |
| Veran Medical Technologies, INC. | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.